GSGT.F Stock Overview
GenSight Biologics S.A., a clinical-stage biotechnology company, discovers, develops, and commercializes therapies for mitochondrial and neurodegenerative diseases of the eye and central nervous system.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 2/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
+ 3 more risks
GenSight Biologics S.A. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €0.45 |
| 52 Week High | €0.80 |
| 52 Week Low | €0.0003 |
| Beta | 2.14 |
| 1 Month Change | 0% |
| 3 Month Change | n/a |
| 1 Year Change | n/a |
| 3 Year Change | -94.78% |
| 5 Year Change | n/a |
| Change since IPO | -93.69% |
Recent News & Updates
Recent updates
Shareholder Returns
| GSGT.F | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 0% | -2.8% | -1.7% |
| 1Y | n/a | -0.2% | 22.4% |
Return vs Industry: Insufficient data to determine how GSGT.F performed against the US Biotechs industry.
Return vs Market: Insufficient data to determine how GSGT.F performed against the US Market.
Price Volatility
| GSGT.F volatility | |
|---|---|
| GSGT.F Average Weekly Movement | n/a |
| Biotechs Industry Average Movement | 11.6% |
| Market Average Movement | 6.1% |
| 10% most volatile stocks in US Market | 16.6% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: GSGT.F has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine GSGT.F's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2012 | 23 | Laurence Rodriguez | www.gensight-biologics.com |
GenSight Biologics S.A., a clinical-stage biotechnology company, discovers, develops, and commercializes therapies for mitochondrial and neurodegenerative diseases of the eye and central nervous system. The company develops its products through gene therapy-based mitochondrial targeting sequence and optogenetics technology platforms. Its lead product candidates include LUMEVOQ (GS010), a recombinant AAV2-based gene therapy, which is in Phase III clinical trials for the treatment of leber hereditary optic neuropathy caused by a mutated ND4 gene; and GS030, which is in Phase I/II clinical trial for the treatment of retinitis pigmentosa, as well as in preclinical stage to treat dry age-related macular degeneration.
GenSight Biologics S.A. Fundamentals Summary
| GSGT.F fundamental statistics | |
|---|---|
| Market cap | US$33.26m |
| Earnings (TTM) | -US$27.92m |
| Revenue (TTM) | US$3.20m |
10.4x
P/S Ratio-1.2x
P/E RatioIs GSGT.F overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| GSGT.F income statement (TTM) | |
|---|---|
| Revenue | €3.00m |
| Cost of Revenue | €0 |
| Gross Profit | €3.00m |
| Other Expenses | €29.20m |
| Earnings | -€26.20m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
Jul 23, 2024
| Earnings per share (EPS) | -0.34 |
| Gross Margin | 100.00% |
| Net Profit Margin | -873.33% |
| Debt/Equity Ratio | -79.0% |
How did GSGT.F perform over the long term?
See historical performance and comparison